金河生物
(002688)
| 流通市值：53.50亿 | | | 总市值：55.41亿 |
| 流通股本：7.45亿 | | | 总股本：7.72亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,657,273,697.64 | 1,065,746,197.18 | 519,450,050.36 | 2,174,131,033.42 |
| 营业收入 | 1,657,273,697.64 | 1,065,746,197.18 | 519,450,050.36 | 2,174,131,033.42 |
| 二、营业总成本 | 1,530,578,504.1 | 964,395,552.61 | 469,749,153.26 | 2,058,031,822.73 |
| 营业成本 | 1,105,938,899.22 | 710,820,314.38 | 341,882,724.05 | 1,531,633,205.82 |
| 税金及附加 | 12,101,915.29 | 7,757,666.28 | 3,655,644.77 | 14,618,599.31 |
| 销售费用 | 99,721,319.65 | 65,296,235.34 | 37,182,012.88 | 143,364,417.71 |
| 管理费用 | 197,806,033.33 | 113,141,216.28 | 52,082,015.66 | 246,420,290.01 |
| 研发费用 | 56,656,746.61 | 37,152,241.46 | 19,538,556.28 | 74,002,978.75 |
| 财务费用 | 58,353,590 | 30,227,878.87 | 15,408,199.62 | 47,992,331.13 |
| 其中:利息费用 | 57,420,653.68 | 38,016,127.38 | 18,782,161.6 | 61,100,801.96 |
| 其中:利息收入 | 4,704,772.3 | 3,265,549.19 | 1,535,854 | 8,371,991.81 |
| 加:公允价值变动收益 | 77,664.25 | 41,673.5 | 7,577 | -3,788.5 |
| 加:投资收益 | -631,039.01 | -631,039.01 | -484,445.19 | -1,521,121.93 |
| 资产处置收益 | 13,381.3 | 13,958.62 | -210,334.69 | -363,843.54 |
| 资产减值损失(新) | -17,338,597.73 | -11,141,250.13 | -5,733,133.07 | -24,598,157.68 |
| 信用减值损失(新) | -3,572,694.97 | -1,838,634.9 | 616,691.96 | -6,060,568.25 |
| 其他收益 | 20,099,005.62 | 13,188,026.46 | 6,091,223.78 | 21,180,995.87 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 125,342,913 | 100,983,379.11 | 49,988,476.89 | 104,732,726.66 |
| 加:营业外收入 | 325,635.63 | 250,718.14 | 54,747.77 | 119,207.5 |
| 减:营业外支出 | 1,457,769.99 | 1,156,567.63 | 18,756.6 | 3,355,524.83 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 124,210,778.64 | 100,077,529.62 | 50,024,468.06 | 101,496,409.33 |
| 减:所得税费用 | 11,145,338.59 | 9,480,553.15 | 2,450,428.99 | 7,061,915.41 |
| 六、净利润 | 113,065,440.05 | 90,596,976.47 | 47,574,039.07 | 94,434,493.92 |
| 持续经营净利润 | 113,065,440.05 | 90,596,976.47 | 47,574,039.07 | 94,434,493.92 |
| 归属于母公司股东的净利润 | 113,761,436.1 | 91,020,627.53 | 45,143,153.81 | 86,457,012.48 |
| 少数股东损益 | -695,996.05 | -423,651.06 | 2,430,885.26 | 7,977,481.44 |
| (一)基本每股收益 | 0.15 | 0.12 | 0.06 | 0.11 |
| (二)稀释每股收益 | 0.15 | 0.12 | 0.06 | 0.11 |
| 八、其他综合收益 | -6,794,267.1 | 997,864.75 | -788,082.42 | 7,681,466.61 |
| 归属于母公司股东的其他综合收益 | -5,775,127.04 | 848,185.04 | -669,870.06 | 6,532,762.68 |
| 九、综合收益总额 | 106,271,172.95 | 91,594,841.22 | 46,785,956.65 | 102,115,960.53 |
| 归属于母公司股东的综合收益总额 | 107,986,309.06 | 91,868,812.57 | 44,473,283.75 | 92,989,775.16 |
| 归属于少数股东的综合收益总额 | -1,715,136.11 | -273,971.35 | 2,312,672.9 | 9,126,185.37 |
| 公告日期 | 2024-10-28 | 2024-08-29 | 2024-04-29 | 2024-04-29 |
| 审计意见(境内) | | | | 标准无保留意见 |